Neuro-oncology practice最新文献

{"title":"First report of a clinical and radiologic response to vorasidenib in a patient with isocitrate dehydrogenase-mutant brainstem astrocytoma.","authors":"Hannah Kim, Andrea Gomez, Karan S Dixit","doi":"10.1093/nop/npaf131","DOIUrl":"https://doi.org/10.1093/nop/npaf131","url":null,"abstract":"<p><strong>Background: </strong>IDH (isocitrate dehydrogenase)-mutant gliomas of the brainstem are exceedingly rare. In the INDIGO trial, patients with brainstem gliomas were excluded, thus, no data exists on the use of vorasidenib in this group.</p><p><strong>Case summary: </strong>We describe the case of a 20-year-old female who developed progressive left facial myokymia and binocular horizontal diplopia on leftward gaze over two years. Brain MRI demonstrated a non-enhancing, expansile T2/FLAIR hyperintense lesion in the left greater than right brainstem extending from the dorsal pons into the cervicomedullary junction. The slowly progressive nature of her symptoms and radiologic appearance were most suggestive of a lower-grade, infiltrative neoplasm. She underwent biopsy of the left middle cerebellar peduncle, which confirmed an IDH R132C-mutant astrocytoma, WHO grade 2. With shared decision making, the patient elected to initiate therapy with vorasidenib 40 mg once daily. After six months of treatment, her diplopia and facial myokymia nearly resolved. By eleven months, her symptoms remain well controlled. Brain MRI shows significant reduction in the size of the T2/FLAIR hyperintense lesion.</p><p><strong>Conclusions: </strong>This case is the first to report a favorable clinical and radiologic response to vorasidenib in a patient with an IDH-mutant brainstem astrocytoma, suggesting the potential use of IDH inhibitors in this group.</p>","PeriodicalId":19234,"journal":{"name":"Neuro-oncology practice","volume":"13 2","pages":"428-431"},"PeriodicalIF":2.5,"publicationDate":"2025-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13153679/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147869000","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Visual morbidity, long-term outcome and prognostic factors in infants and young children with optic pathway low-grade glioma.","authors":"Stefania Picariello, Bronwen Walters, Richard Bowman, Mette Jorgensen, Olga Slater, Patricia O'Hare, Helen Alexandra Spoudeas, Kristian Aquilina, Yen-Ching Chang, Manuela Cerbone, Hoong-Wei Gan, Felice D'Arco, Christine Dahl, Katherine Green, Darren Hargrave, Enrico Opocher","doi":"10.1093/nop/npaf129","DOIUrl":"https://doi.org/10.1093/nop/npaf129","url":null,"abstract":"<p><strong>Background: </strong>Optic pathway gliomas (OPG) in infants and young children (IYC) are associated with significant long-term morbidity, but visual outcomes in this high-risk group remain poorly characterized.</p><p><strong>Methods: </strong>We retrospectively reviewed clinical, ophthalmologic, and radiological data from 81 children diagnosed with OPG before age 3 and followed at a single institution between 1981 and 2020. Best-corrected visual acuity (BCVA) was assessed using age-adjusted criteria and REiNS recommendations. Survival outcomes and prognostic factors were analysed using Kaplan-Meier and regression models.</p><p><strong>Results: </strong>Thirty-one children underwent initial surgery, four of whom had no further treatment. Sixty-six were treated with chemotherapy (62) or radiotherapy (4) at diagnosis, while 11 were initially observed. At presentation, 74% had abnormal-for-age BCVA, and 33% met criteria for bilateral visual impairment. After a median 11-year follow-up, 81.5% showed abnormal vision, 45.7% were visually impaired, and 26% were bilaterally blind. Only 36% showed BCVA improvement, while 32% worsened. The 10-year visual progression-free survival was 41.3%. Post-chiasmatic tumor involvement was the only independent predictor of visual progression (HR 2.91, <i>P</i> = .033). Most cases of visual deterioration occurred within the first 2 years, but late events up to 16 years post-diagnosis were also observed.</p><p><strong>Conclusions: </strong>IYC with OPG suffer from substantial and often irreversible visual morbidity, frequently already present at diagnosis. Despite long-term survival, functional visual outcomes remain poor. Our findings underscore the urgent need for earlier, vision-directed interventions and long-term visual monitoring. This large single-center cohort provides a robust benchmark for future prospective studies.</p>","PeriodicalId":19234,"journal":{"name":"Neuro-oncology practice","volume":"13 3","pages":"608-619"},"PeriodicalIF":2.5,"publicationDate":"2025-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13268981/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148272459","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"AI-based framework to fuse pre-RT brain metastases contours with follow-up MRI to improve post-RT assessment.","authors":"Yogesh Kumar, Kayla L Steed, Ho-Hsin Chang, Udbhav Ram, Gaurav N Rathi, Katherine A Heinzman, Ritish Nedunoori, Farnaz Rahim Li, Richard A Popple, Rex Cardan, Christopher D Willey, Drexell H Boggs, John B Fiveash, Carlos E Cardenas","doi":"10.1093/nop/npaf126","DOIUrl":"10.1093/nop/npaf126","url":null,"abstract":"<p><strong>Background: </strong>Brain metastases (BMs) patients often receive multiple courses of radiotherapy (RT). Comparing follow-up imaging with RT plans is time-intensive and currently not possible in picture archiving and communication system (PACS). In this study, we aim to develop an automated tool to overlay pre-RT tumor contours onto follow-up MRI in the PACS to support response assessment and identification of untreated metastases, reducing review complexity and time.</p><p><strong>Methods: </strong>We built an AI-driven workflow that registers planning CT to follow-up MRI and propagates treated-lesion contours; outputs are exported as PACS-compliant DICOM. Performance was evaluated in 40 patients: 20 underwent quantitative comparison between manual and automated registrations using Dice similarity coefficient (DSC) and mean surface distance (MSD), following AAPM TG-132 guidelines; 20 additional patients (5-35 lesions per patient) underwent clinical evaluation of follow-up and pre-RT lesions contours visualization in PACS. Three physicians assessed these cases to measure review time and inter-observer agreement in treatment response classification (improved/stable vs indeterminate).</p><p><strong>Results: </strong>The workflow successfully registered all CT-MRI pairs. Mean DSC/MSD was: brain 0.97 ± 0.01/0.0 ± 0.0 mm, brainstem 0.89 ± 0.03/0.1 ± 0.1 mm, and gross tumor volumes 0.65 ± 0.18/0.6 ± 0.4 mm. Average physician review time per case decreased from 7.97 to 3.95 min with the automated workflow, and full inter-physician agreement increased from 72.4% to 93.5%.</p><p><strong>Conclusion: </strong>We developed and validated an AI-based tool that accurately fuses pre-RT contours with follow-up MRI for BMs, addressing a key gap in current PACS systems. The workflow significantly reduced review time per lesion and enhanced inter-physician agreement, and has the potential to enable faster, more consistent multidisciplinary follow-up assessment.</p>","PeriodicalId":19234,"journal":{"name":"Neuro-oncology practice","volume":"13 3","pages":"497-505"},"PeriodicalIF":2.5,"publicationDate":"2025-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13161908/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147931896","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Postoperative ischemia and neurological deficits after glioma resection: A systematic review and meta-analysis.","authors":"Arthur T J van der Boog, Eva E van Grinsven, Matea Rados, Tom J Snijders, Joost J C Verhoeff, Pierre A Robe","doi":"10.1093/nop/npaf122","DOIUrl":"10.1093/nop/npaf122","url":null,"abstract":"<p><strong>Background: </strong>Postoperative ischemia is a known complication of glioma resection that is registered by diffusion-weighted MRI (DWI) and can lead to new neurological deficits. The aim of this review was to assess the incidence of ischemia after glioma resection and identify potential risk factors and consequences.</p><p><strong>Methods: </strong>A systematic review was conducted according to the PRISMA guidelines. Cohort studies reporting surgeries for WHO grade II-IV gliomas followed by postoperative DWI within 72 h were included. Pooled, weighted incidences for postoperative ischemia and neurological deficits were calculated with a binary random-effects model.</p><p><strong>Results: </strong>In total, 29 studies were included in this review, of which 25 studies with 2729 cases were included for meta-analysis. Pooled incidence was 48% (95% confidence interval [CI]: 36%-59%) for postoperative ischemia and 32% (95% CI: 23%-41%) for postoperative transient and persistent neurological deficits. Postoperative ischemia with any neurological deficits occurred in 15% (95% CI: 10%-20%) of patients, postoperative ischemia without neurological sequelae in 26% (95% CI: 17%-35%), and 41% (95% CI: 30%-52%) of patients with postoperative ischemia experienced neurological deterioration. Postoperative ischemia was associated with opercular, insular, or temporal tumor locations, proximity to and infiltration of perforating arteries, prior radiotherapy, age and intraoperative hemodynamic decline, among others. Postoperative ischemia was related to neurological deterioration, recurrence, and overall survival in some studies.</p><p><strong>Conclusion: </strong>Postoperative ischemia is a quite frequent complication of glioma resection affecting functional outcome and disease progression. Potential risk factors may give insight in preventive measures and future studies with precise spatial analyses could identify vulnerable brain regions.</p>","PeriodicalId":19234,"journal":{"name":"Neuro-oncology practice","volume":"13 3","pages":"452-464"},"PeriodicalIF":2.5,"publicationDate":"2025-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13161909/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147931930","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identifying predictive factors for radiation necrosis vs local recurrence in biopsy-proven enlarging lesions post-stereotactic radiosurgery for brain metastases.","authors":"Ariel T Gonzalez, Aden P Haskell-Mendoza, Ellery H Reason, Joshua D Jackson, Chunhao Wang, Eugene J Vaios, Claire I Bradbury, Jingtong Zhao, James E Herndon Ii, Peter E Fecci","doi":"10.1093/nop/npaf125","DOIUrl":"https://doi.org/10.1093/nop/npaf125","url":null,"abstract":"<p><strong>Background: </strong>Stereotactic radiosurgery (SRS) remains the standard of care for brain metastases (BM), offering effective local control with fewer neurocognitive side effects. However, distinguishing radiation necrosis (RN) from local recurrence (LR) is challenging in lesions that enlarge post-SRS. Identifying clinical and treatment-related factors associated with RN vs LR may improve decision-making. Prior smaller studies have suggested time to progression may help differentiate RN from LR; we aimed to reassess this observation and explore other factors in a larger cohort.</p><p><strong>Methods: </strong>We retrospectively analyzed patients treated with SRS for BM between 2011 and 2022 who later underwent biopsy, with or without LITT, for imaging-suspected RN vs LR. Data included demographics, clinicopathologic characteristics, SRS-treatment parameters, and biopsy results.</p><p><strong>Results: </strong>Among the identified 145 patients with 151 progressive lesions, biopsy confirmed RN in 93 (61.6%) and LR in 58 (38.4%). A subset of lesions (<i>n</i> = 108) had complete dosimetric data. Median age at SRS was 62 years, with a median SRS-biopsy interval of 13 months. The median prescribed dose was 20 Gy for single-fraction and 27.5 Gy for hypofractionated regimens. Multivariable models identified age ≥65 and SRS to biopsy interval ≥9 months as predictors of RN in the full cohort. In the subset group with detailed dosimetric data, V12Gy ≥ median (4.64 cm³) additionally predicted RN and improved model fit.</p><p><strong>Conclusion: </strong>We identified older age, a longer SRS to biopsy interval, and higher V12Gy as predictors of RN. Our predictive models incorporate these variables and may support clinical decision-making, improve diagnostic accuracy, and optimize patient outcomes.</p>","PeriodicalId":19234,"journal":{"name":"Neuro-oncology practice","volume":"13 3","pages":"478-488"},"PeriodicalIF":2.5,"publicationDate":"2025-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13268959/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148272300","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pediatric high-grade gliomas: Where do neurofibromatosis type one-associated high-grade gliomas stand in the landscape?","authors":"Samuele Renzi, Eric Bouffet","doi":"10.1093/nop/npaf117","DOIUrl":"10.1093/nop/npaf117","url":null,"abstract":"","PeriodicalId":19234,"journal":{"name":"Neuro-oncology practice","volume":"13 1","pages":"1-2"},"PeriodicalIF":2.5,"publicationDate":"2025-12-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12965657/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147378026","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Creating a neuro-oncology framework for an empowered and engaged peer volunteer patient community.","authors":"Naomi Hoffer, Eduardo Rodriguez Almaraz, Lacy Fetting, Jennie Taylor, Susan Chang","doi":"10.1093/nop/npaf119","DOIUrl":"10.1093/nop/npaf119","url":null,"abstract":"<p><strong>Background: </strong>Brain tumor patients often face isolation, identity loss, and existential distress. Peer-to-peer support can address these challenges, yet little guidance exists for supporting neuro-oncology patient volunteers who provide such care. Herein we describe our institutional experience with an innovative program that supports volunteers and provides for peer-to-peer initiatives in neuro-oncology.</p><p><strong>Methods: </strong>In 2020, the UCSF Sheri Sobrato Brain Cancer Survivorship Program launched a peer support initiative pairing brain tumor patients with trained volunteer peers. To support volunteers, the program offers an optional ongoing community facilitated by a cancer coach trainer, a neuropsychologist, and a social worker. Weekly sessions included training, check-ins, group discussions, feedback opportunities, and an annual feedback survey.</p><p><strong>Results: </strong>Between August 2020 and October 2023, six cohorts (46 peer volunteers) were trained, with a total of 132 peer matches made for 116 patient requests. Most volunteers (70%) attended 11 or more weekly meetings. All respondents to the annual feedback survey (<i>n</i> = 30) expressed high satisfaction with the program. Volunteers highlighted benefits including mutual support, a sense of community, meaningful contributions, personal growth, and empowerment.</p><p><strong>Conclusion: </strong>In our experience, patient peer volunteer programs show promise in reducing isolation and restoring purpose. This unique 3-year pilot suggests that ongoing group support and training are a plausible and effective way to enhance a peer-to-peer volunteer program. Future efforts will focus on developing a structured curriculum for neuro-oncology patient peer volunteers and prospective evaluation of the impact of the program.</p>","PeriodicalId":19234,"journal":{"name":"Neuro-oncology practice","volume":"13 2","pages":"363-372"},"PeriodicalIF":2.5,"publicationDate":"2025-11-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13153703/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147869061","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Thickened but unclear: Clinical course of isolated pituitary stalk thickening in the pediatric age group.","authors":"Hannah K Miller, Vikram P Rajan, Christopher Blunden, Deniz Altinok, Hamza S Gorsi","doi":"10.1093/nop/npaf118","DOIUrl":"https://doi.org/10.1093/nop/npaf118","url":null,"abstract":"<p><strong>Background: </strong>The incidence of pituitary stalk thickening (PST) has increased in recent years due to the increased utilization of diagnostic MRI of the brain. The clinical significance of PST, appropriate diagnostic workup, and clinical course for these patients is not well documented.</p><p><strong>Methods: </strong>After Institutional Review Board approval, we reviewed the pediatric tumor board and pediatric endocrinology clinic records between 2003 and 2024 to identify patients with PST. We followed the clinical course of these patients to collect applicable data.</p><p><strong>Results: </strong>A total of 29 patients were identified with PST; 11 were excluded due to additional MRI findings, and out of 18 selected patients, 9 were females (50%). Initial diagnostic workup included complete blood count (CBC), basic metabolic panel, serum and cerebrospinal fluid (CSF) tumor markers (AFP, β-hCG), and skeletal survey. With the initial workup, no patient was diagnosed with neoplasm. Patients were followed with serial MRIs. Five patients (27.7%) displayed progression of PST, warranting biopsy (2 germinomas, 2 Langerhans cell histiocytosis, and 1 inconclusive). The median time to biopsy was 8 months (range 4-26 months). All the patients diagnosed with neoplasm had central diabetes insipidus at presentation, and 3 went on to develop additional endocrine abnormalities. Ten patients had stable PST over a median follow-up period of 19 months (range 0-81 months), and 3 patients had complete resolution of PST during the follow-up period.</p><p><strong>Conclusion: </strong>Most isolated PST among pediatric patients remain stable over time. Serial monitoring of patients with isolated PST can be safe, and not all cases of PST warrant upfront biopsy.</p>","PeriodicalId":19234,"journal":{"name":"Neuro-oncology practice","volume":"13 2","pages":"408-414"},"PeriodicalIF":2.5,"publicationDate":"2025-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13153699/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147869138","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Seizure prophylaxis in glioma surgery (SPRING): A multi-center, unblinded, randomized trial.","authors":"Michael D Jenkinson, Helen Bulbeck, Jackie Burns, Alasdair G Rooney, Richard Dobbie, Jade Carruthers, Sarah Lessels, Rachael Watson, Ciara Gribben, Tomos Robinson, Luke Vale, Gerard Thompson, Sara C Erridge, Colin Watts, Anthony G Marson, Robin Grant","doi":"10.1093/nop/npaf114","DOIUrl":"10.1093/nop/npaf114","url":null,"abstract":"<p><strong>Background: </strong>50%-80% of glioma patients will have seizures. Guidelines recommend against prophylactic anti-seizure medication, but levetiracetam is frequently prescribed. Our aim was to determine the effectiveness of 12-month prophylactic levetiracetam at reducing seizure risk.</p><p><strong>Methods: </strong>Seizure-naïve patients undergoing glioma surgery were randomized (1:1) to 12-month levetiracetam or no prophylaxis and followed until death or a maximum of 18-months. The primary outcome was 1-year risk of first seizure. Patients who died within 12 months of randomization without experiencing a seizure were excluded from the primary outcome analysis. Target accrual was 804 participants. The trial was registered (ISRCTN 49474281 and EudraCT 2018-001312-30).</p><p><strong>Results: </strong>Between October 10, 2019 and August 30, 2022, 96 patients, from 24 to 79 years of age, were randomized to levetiracetam (<i>n</i> = 49) or no prophylaxis (<i>n</i> = 47). The trial closed early due to slow accrual and the Covid pandemic. In the levetiracetam group, 17 patients had a seizure and 32 did not (19 survived ≥12 months, 13 died within 12 months). In the no-prophylaxis group, 15 patients had a seizure and 30 did not (21 survived ≥12 months, 9 died within 12 months). Seventeen of the 36 evaluable levetiracetam patients (47%) had a seizure, compared with 15 of 36 evaluable no-prophylaxis patients (41%) (OR: 1.25, 95% CI, 0.49-3.21, <i>P</i> = .64). There were no levetiracetam-related serious adverse events.</p><p><strong>Conclusions: </strong>The seizure prophylaxis in glioma surgery (SPRING) trial provides no evidence of a difference between levetiracetam and no prophylaxis in the 12-month seizure risk in patients undergoing glioma surgery, but the study was underpowered. The role of prophylactic anti-seizure medication remains undefined.</p>","PeriodicalId":19234,"journal":{"name":"Neuro-oncology practice","volume":"13 2","pages":"252-261"},"PeriodicalIF":2.5,"publicationDate":"2025-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13153692/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147869102","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Methodological aspects of economic evaluations and health economic models in glioblastoma: A systematic literature review.","authors":"Erika Országh, Judit Józwiak-Hagymásy, Tamás Dóczi, Dóra Mezei, Bertalan Németh, Hédi Varga, Attila Tordai, Tomas Kazda, Thierry Gorlia, Caroline Quoilin, Matthias Preusser, Giuseppe Minniti, Marcell Csanádi","doi":"10.1093/nop/npaf113","DOIUrl":"10.1093/nop/npaf113","url":null,"abstract":"<p><strong>Background: </strong>Glioblastoma is considered one of the deadliest malignant solid tumors. The disease severity and the treatment intensity place a significant burden on patients, their family and caregivers, and the health systems. This study aimed to review the methodological aspects and quality of economic evaluations and health economic models in glioblastoma with a special focus on Europe and North America.</p><p><strong>Methods: </strong>A search was performed covering Medline (via PubMed), Embase, Scopus, Cochrane Library, and PROSPERO. Gray literature search and snowball sampling were also conducted. Studies were eligible if they included glioblastoma patients, contained data on economic evaluations, and were in our geographical focus. The protocol was registered in PROSPERO (ID: CRD42023488181).</p><p><strong>Results: </strong>The review of 4052 records resulted in 19 peer-reviewed articles, 1 health technology assessment agency document, 2 conference posters, and 1 thesis. Most studies investigated pharmaceuticals in combination with radiotherapy (<i>n</i> = 7). Five studies focused on tumor-treating fields in combination with maintenance temozolomide. Most studies investigated newly diagnosed patients (<i>n</i> = 18). Economic modeling was used in 15 cases; the majority used the \"traditional\" 3-state Markov cohort or partitioned-survival modeling approach (health states: progression-free, progressed, dead). Input data, particularly for utilities, were outdated in many cases. We identified only 2 studies with societal perspective, and these had limited scope.</p><p><strong>Conclusion: </strong>Our review identified gaps in the literature related to the economic evaluations on relapsed glioblastoma patients and to comprehensive assessments using a societal perspective. We also concluded that there is a lack of relevant, high-quality, and up-to-date utility data for glioblastoma in the studies.</p>","PeriodicalId":19234,"journal":{"name":"Neuro-oncology practice","volume":"13 2","pages":"238-251"},"PeriodicalIF":2.5,"publicationDate":"2025-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13153701/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147869033","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}